Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs

More in Business

• Cabinet nod for Rs 2,814 cr plan to support critical mineral processing

  This strategic initiative seeks to mitigate supply chain risks by establishing domestic infrastructure to refine essential raw materials. Because global refining capacity is currently concentrated in only a few geographies, the move directly targets the nation's reliance on foreign processing hubs. Developing these facilities will bolster domestic supply security and spur private industrial investments over the coming decade.

  1 min read
• AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say

  The pharmaceutical giant's multi-billion-dollar approach targets a specialized developer in the expanding market for weight-loss treatments. This strategic bid represents an effort to secure Rhythm's drug assets, though people with knowledge of the situation note that critical terms remain unconfirmed. Stakeholders are monitoring whether the offer will progress into a finalized acquisition.

  1 min read
• Rheinmetall cuts 2026 sales forecast again as Boxer order slips

  Delays surrounding an important vehicle contract have forced the defense contractor to recalibrate its medium-term financial targets. This latest reduction directly reflects the commercial fallout from postponed procurement timelines for critical military hardware. Investors and defense industry watchers now face adjusted expectations for the firm's growth through the middle of the decade.

  1 min read